MATK

In January 2025, several significant mergers and acquisitions (M&A) took place in the biopharmaceutical industry. These transactions not only reflect the strategic positioning of major companies in specific therapeutic areas but also demonstrate the industry's continued focus on innovative technologies and unmet medical needs. Lantheus Holdings, a leader in the field of radiopharmaceuticals, has significantly strengthened its market position and technological portfolio through a series of acquisitions. First, Lantheus completed the acquisition of Evergreen Theragnostics, bringing advanced manufacturing infrastructure and the PET drug Octevy, used for diagnosing neuroendocrine tumors, thereby further enriching its product line. Subsequently, Lantheus plans to acquire Life Molecular Imaging (LMI) for $350 million in an upfront payment, aiming to enhance its competitiveness in the Alzheimer's disease diagnostic market and expand its influence in oncology. At the same time, other major pharmaceutical companies are taking action to consolidate their leadership in key areas. Johnson & Johnson, Eli Lilly, and GlaxoSmithKline (GSK) have each strengthened their product portfolios in neuroscience, precision oncology, and gastrointestinal cancer treatment by acquiring Intra-Cellular Therapies, Scorpion Therapeutics, and IDRx, respectively. Additionally, the acquisition of Tavros Therapeutics by Vividion Therapeutics and the merger between Salarius Pharmaceuticals and Decoy Therapeutics reflect the industry's emphasis on cutting-edge technological platforms, particularly those offering differentiated advantages. Notably, the sale of Serina Therapeutics' subsidiary UniverXome Bioengineering to Juvenescence illustrates that, when facing financial challenges, asset restructuring and strategic partnerships can be essential strategies for companies. Although Biogen's non-binding acquisition proposal for Sage Therapeutics was ultimately rejected, it highlighted the importance of the existing collaboration between the two companies and the potential for deeper integration. 1.Lantheus Announces Completion of Acquisition of Evergreen Theragnostics On January 29, 2025, U.S. radiopharmaceutical company Lantheus announced the completion of its acquisition of Evergreen Theragnostics for a total transaction value of $1 billion, which includes an upfront payment of $250 million and potential additional installment payments of up to $752.5 million. This marks Lantheus' fifth acquisition since January 2024, aimed at enhancing its production capacity and technological capabilities in the radiopharmaceuticals sector. The acquisition enables Lantheus to gain Evergreen's radioligand therapy (RLT) manufacturing infrastructure, which supports both clinical trial needs and large-scale commercial production, reducing dependence on third-party manufacturing partners. The acquisition also includes Octevy, a PET diagnostic drug currently in the registration phase, used for detecting neuroendocrine tumors in both adult and pediatric patients. Lantheus noted that Octevy could serve as a complement to PNT2003 (lutetium Lu 177 edotreotide), a therapeutic drug developed by the company in collaboration with POINT Biopharma, which is currently undergoing Phase III trials for neuroendocrine tumors. This combination provides Lantheus with a more comprehensive product line in the neuroendocrine tumor treatment field, enhancing the company's competitiveness in this area. 2.Lantheus Holdings Announces Plan to Acquire Life Molecular Imaging (LMI) for $350 Million Upfront On January 17, 2025, Lantheus Holdings announced its plan to acquire Life Molecular Imaging (LMI) for an upfront payment of $350 million, with the potential for additional milestone and contingent payments of up to $400 million. This strategic acquisition aims to strengthen Lantheus' position in the Alzheimer's disease diagnostic market, particularly by acquiring LMI's key product, Neuraceq, a commercial diagnostic agent used to detect β-amyloid plaques in Alzheimer's patients. The transaction brings five significant assets to Lantheus, with Neuraceq, as a commercialized product, enabling the company to enter the Alzheimer's diagnostic market at least one year ahead of schedule. In addition, Lantheus will gain access to a diagnostic and therapeutic radiopharmaceutical combination targeting the gastrin-releasing peptide receptor, which is of particular relevance to breast and prostate cancers. These actions not only reinforce Lantheus' presence in the neurodegenerative disease diagnostic space but also complement the company's existing oncology product line, such as the prostate cancer diagnostic drug Pylarify. Through this acquisition, Lantheus further solidifies its leadership position in the radiopharmaceutical industry and injects new vitality into its diagnostic capabilities in Alzheimer's and other disease areas. This move reflects Lantheus' commitment to advancing medical imaging technologies and its dedication to developing more accurate and effective diagnostic tools, which is expected to have a positive impact on early detection and improving patient outcomes. 3.Serina Therapeutics Announces Sale of Subsidiary UniverXome Bioengineering to Juvenescence On January 16, 2025, Serina Therapeutics announced the sale of its subsidiary UniverXome Bioengineering to Juvenescence, a company focused on anti-aging, in order to repay a total debt of $11.2 million. This transaction is aimed at alleviating Serina's financial burden in the new year and refocusing its resources on its core business. UniverXome holds assets that were left over from the reverse merger with AgeX Therapeutics, a publicly traded company that has long faced financial difficulties. Before merging with Serina, AgeX Therapeutics had repeatedly warned that its funds were running out and had been seeking solutions, ultimately completing a merger plan with Serina in August 2023. While this merger provided a lifeline for AgeX, it also transferred the associated financial pressure to Serina. Notably, Juvenescence had previously provided tens of millions of dollars in loans to AgeX, indicating its interest in and support for AgeX and its technologies. This asset sale is not focused on specific drugs or therapeutic areas but revolves around addressing the complex financial relationships and asset restructuring between the companies. By selling UniverXome to Juvenescence, Serina not only reduces its debt burden but also allows Juvenescence to acquire certain valuable biotechnology technologies or intellectual property previously held by AgeX, although specific details were not disclosed in the announcement. This move reflects a broader trend in the biotechnology industry of addressing financial challenges through asset restructuring and strategic partnerships. 4.Johnson & Johnson Announces Acquisition of Intra-Cellular Therapies On January 13, 2025, Johnson & Johnson announced the acquisition of Intra-Cellular Therapies to strengthen its leadership in the neuroscience field. The core of this acquisition is CAPLYTA® (lumateperone), the first and only FDA-approved drug for the adjunctive and monotherapy treatment of bipolar I and II depression, as well as for the treatment of schizophrenia in adults. This acquisition not only enhances Johnson & Johnson's product line in neuroscience but also lays the foundation for sales growth over the next few years. As an important treatment option, CAPLYTA® has already been submitted for a supplemental new drug application (sNDA) to expand its use as an adjunctive treatment for major depressive disorder (MDD). If approved, CAPLYTA® is expected to become one of the standard treatments for most common types of depression, further expanding its market influence. Moreover, CAPLYTA®'s peak annual sales potential exceeds $5 billion, significantly boosting Johnson & Johnson's financial performance and helping the company exceed analysts' growth expectations. In addition to its current indications, CAPLYTA® has shown potential in clinical studies for generalized anxiety disorder, Alzheimer's-related psychosis, and agitation symptoms. These additional indications not only offer a broader market prospect for CAPLYTA® but also demonstrate Johnson & Johnson's commitment to developing treatments for a variety of neurological disorders. Through this strategic move, Johnson & Johnson is steadily reinforcing its leadership in the neuroscience sector. 5.Eli Lilly Announces Final Acquisition Agreement with Scorpion Therapeutics On January 13, 2025, Eli Lilly announced that it had reached a final agreement to acquire Scorpion Therapeutics and its development of the mutation-selective PI3Kα inhibitor project, STX-478. STX-478 is a once-daily oral medication currently in Phase 1/2 clinical trials, aimed at treating 30-40% of hormone-positive breast cancer patients, with the potential to become a best-in-class treatment option. This acquisition will enhance Eli Lilly's oncology portfolio and provide new momentum for its development in precision oncology. Under the terms of the agreement, Eli Lilly will pay up to $2.5 billion in cash to complete the acquisition of Scorpion, including upfront payments and subsequent payments based on achieving specific regulatory and sales milestones. Additionally, Scorpion will spin off a new entity that will hold assets related to its employees and non-PI3Kα projects, which will be owned by existing shareholders and led by Scorpion's current management team, focusing on the discovery and delivery of precision drug combinations. Through this transaction, Eli Lilly aims to leverage Scorpion's expertise and its own to accelerate the development of STX-478, improving treatment outcomes for patients with various solid tumors driven by PI3Kα mutations. STX-478, as a differentiated mutation-selective PI3Kα inhibitor, selectively targets the PI3Kα pathway in cancer cells rather than healthy cells, overcoming key limitations of existing drugs targeting this pathway. This characteristic makes STX-478 poised to provide deeper pathway inhibition and higher tolerance, offering hope for patients in need of effective and safe targeted therapies for the PI3Kα pathway. Eli Lilly hopes to make significant progress in the treatment of breast cancer and other advanced solid tumors through this acquisition. 6.GlaxoSmithKline (GSK) Announces Agreement to Acquire IDRx On January 13, 2025, GlaxoSmithKline (GSK) announced an agreement to acquire IDRx, a Boston-based clinical-stage biopharmaceutical company focused on developing precision therapies for gastrointestinal stromal tumors (GISTs). The core of this acquisition is IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat GIST and target all key primary and secondary KIT mutations, addressing an unmet need in current treatments. GSK will pay up to $1.15 billion, including $1 billion in upfront payments and potentially an additional $150 million contingent upon successful regulatory approval. IDRX-42 is considered a best-in-class drug due to its broad coverage of KIT mutations in GIST patients and its potential to improve tolerance, overcoming the limitations of existing therapies in terms of recurrence and resistance. Preliminary clinical trials have shown promising antitumor activity and manageable safety in advanced GIST patients, particularly in those receiving second-line or later treatments, with an objective response rate of 29%. Through this acquisition, GSK not only strengthens its portfolio in the gastrointestinal cancer space but also reaffirms its commitment to addressing significant unmet medical needs. This acquisition reflects GSK's strategic goal of identifying and acquiring potential optimal molecules with targeted mechanisms of action to support the company’s long-term growth objectives through 2031 and beyond. The addition of IDRx brings advanced research and development capabilities, particularly in the area of developing efficient and selective targeted therapies. Additionally, IDRx’s other investors and supporters, including Andreessen Horowitz and Casdin Capital, further validate the company's technical expertise and market potential. This partnership is expected to further advance the development of treatments for GIST and other related cancers. 7.Bausch + Lomb Corporation's Subsidiary Completes Acquisition of Whitecap Biosciences, LLC On January 13, 2025, Bausch + Lomb Corporation announced that its subsidiary had completed the acquisition of Whitecap Biosciences, LLC to enhance its research and development capabilities in the ophthalmic treatment field. The acquisition focuses on two innovative therapies currently in development for glaucoma and geographic atrophy (GA), both significant causes of severe vision loss. Through this acquisition, Bausch + Lomb gains Whitecap Biosciences' efficient α-2 adrenergic agonist WB007, which has successfully completed Phase II clinical trials for the treatment of glaucoma, with plans for further clinical research targeting both glaucoma and GA. While the specific terms of the transaction were not disclosed, Bausch + Lomb has indicated that the acquisition will help address unmet medical needs and significantly improve current care standards, especially in slowing or even reversing vision loss caused by glaucoma. Whitecap Biosciences, since its founding in 2015, has focused on developing new therapies for severe eye diseases, including glaucoma and GA. Dr. Scott Whitcup, founder of Whitecap Biosciences, emphasized the importance of partnering with Bausch + Lomb, believing it will accelerate the development of these promising therapies and lead to better visual outcomes for patients. This strategic acquisition not only reflects Bausch + Lomb’s commitment to finding and providing advanced ophthalmic treatments but also strengthens its leadership position in the global eye care market. 8.Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement On January 13, 2025, Salarius Pharmaceuticals, Inc. and Decoy Therapeutics, Inc. announced a definitive merger agreement, under which Decoy will merge with a wholly owned subsidiary of Salarius, and the combined company will be named Decoy Therapeutics. The merger aims to accelerate the clinical development of peptide-drug conjugates (PDCs) utilizing Decoy’s IMP3ACT™ platform, which integrates machine learning (ML) and artificial intelligence (AI) tools to design and manufacture innovative therapies, particularly targeting respiratory viruses and cancer. Decoy Therapeutics focuses on developing next-generation peptide-drug conjugates, with a product pipeline that includes therapies for respiratory infectious diseases and gastrointestinal oncology indications. Through this merger, Salarius’ oral small-molecule protein degrader SP-3164 will also be incorporated into highly targeted peptide-based proteolysis-targeting chimeras (PROTACs) candidates. Additionally, Salarius’ ongoing development of sellidemstat for hematologic cancer will continue to be supported, and its strategic alternatives will be evaluated. Although the specific transaction amount was not disclosed in the announcement, the merged company will be jointly led by senior executives from both companies, including Decoy’s CEO, Frederick “Rick” Pierce, and other core team members. Following the merger, the new company’s board will be composed of Rick Pierce, Barbara Hibner, and three independent directors, reflecting the spirit of collaboration and planning for future growth. David Arthur, President and CEO of Salarius Pharmaceuticals, emphasized that after a comprehensive strategic review, they believe the merger with Decoy Therapeutics represents the best opportunity to create significant value, not only based on the science behind Decoy’s peptide-drug conjugate technology but also due to its strong management team. This merger marks an important milestone for shareholders and presents new possibilities to address unmet needs across various therapeutic areas. 9.Biogen Announces Plan to Acquire All Outstanding Shares of Sage Therapeutics at $7.22 per Share On January 10, 2025, Biogen announced its intention to acquire all of the outstanding shares of Sage Therapeutics at a price of $7.22 per share. This offer represents a premium of approximately 30% over Sage’s closing stock price at the time, with a total estimated valuation of approximately $469 million. Upon receiving the proposal, the Sage board stated that it would carefully review and evaluate Biogen’s offer in consultation with its independent financial and legal advisors, in accordance with its fiduciary duties, to determine the course of action that is in the best interests of the company and all its shareholders. However, by January 27, 2025, the Sage Therapeutics board unanimously rejected Biogen’s non-binding acquisition proposal. Despite this, Sage’s stock price rose following the announcement, reflecting positive market sentiment toward the potential transaction. It is noteworthy that Sage and Biogen have an existing collaboration, jointly developing and marketing Zurzuvae for the treatment of postpartum depression (PPD)/major depressive disorder (MDD) and SAGE-324 for essential tremor. This acquisition proposal could be part of Biogen’s strategy to further consolidate its position in the central nervous system (CNS) disease space. However, Sage believes that Biogen’s offer undervalues the company and may seek to maintain its independence to better develop its business. Furthermore, Sage has attempted to block Biogen’s acquisition efforts through legal means, indicating its strong opposition to the acquisition. 10.Veralox Therapeutics Announces Exclusive Agreement with Nudge Therapeutics On January 9, 2025, clinical-stage biotechnology company Veralox Therapeutics announced an exclusive agreement with Nudge Therapeutics to acquire the latter and its preclinical series of cGAS (cyclic GMP-AMP synthase) inhibitors. This deal enables Veralox to leverage Nudge's novel small-molecule cGAS inhibitors, which are designed to prevent the overproduction of type I interferons associated with inflammation and autoimmune diseases, thus expanding its product portfolio. While the specific financial terms were not disclosed in the announcement, the agreement stipulates that Veralox will be responsible for continuing the development of Nudge's cGAS inhibitors, with a comprehensive acquisition of Nudge Therapeutics upon reaching specific downstream milestones. One of Veralox's main focuses is VLX-1005, a new therapy targeting the 12-lipoxygenase (12-LOX) pathway, which is expected to achieve clinical proof of concept (PoC) by 2025. This transaction is intended to bolster Veralox's research and development capabilities in treating severe autoimmune and inflammatory diseases. Robert Lowery, CEO of Nudge Therapeutics, emphasized the importance of Veralox's expertise in advancing the cGAS program, while Jonathan Mow, CEO of Veralox, noted that the potential applications of cGAS inhibitors span a range of inflammation-related diseases, including autoimmune, metabolic, cardiovascular, rare diseases, and neurodegenerative conditions, which align closely with Veralox's strategic goals. As such, this agreement not only expands Veralox’s product portfolio but also opens new possibilities for future drug development. 11.Vividion Therapeutics Announces Acquisition of Tavros Therapeutics On January 8, 2025, Vividion Therapeutics announced its acquisition of Tavros Therapeutics, aiming to significantly enhance its functional genomics capabilities and further advance its drug discovery platform. This acquisition will enable Vividion to utilize Tavros' proprietary genomic screening methods to identify new drug targets and support the discovery and translational efforts for known targets, particularly in oncology. Although the specific financial terms were not disclosed, this transaction will integrate Tavros' functional and computational genomics technologies into Vividion's platform, accelerating the development of novel therapeutic solutions. Vividion, a wholly owned subsidiary of Bayer, specializes in developing small-molecule therapies targeting high-value, hard-to-drug targets, and this acquisition further solidifies its position in precision oncology and immunology. Notably, Bayer completed the full acquisition of Vividion for approximately $2 billion in August 2021, highlighting the interest of large pharmaceutical companies in small biotech firms with innovative technologies and potential. The acquisition of Tavros represents a significant step in expanding Vividion’s R&D capabilities and technological assets, reinforcing the trend of driving research progress through mergers and acquisitions, and its firm commitment to advancing new drug development. 12.Predictive Oncology Inc. Announces Binding Letter of Intent with Renovaro, Inc. On January 6, 2025, Predictive Oncology Inc. announced that it has signed a binding letter of intent with Renovaro, Inc. to acquire Predictive Oncology by exchanging its shares for a newly created series of preferred stock issued by Renovaro. This transaction aims to combine the expertise of both companies in AI-driven drug discovery and multi-omics data processing to improve patient prognosis across various cancer indications while reducing operating costs by more than 30% in the short term. Under the terms of the agreement, Predictive Oncology’s shareholders will receive Renovaro’s newly issued preferred stock on a 1:1 basis. These preferred shares can be converted into freely tradable common stock of Renovaro or redeemed under certain conditions. Renovaro must raise at least $15 million, and the transaction is subject to the formal approval of Predictive Oncology’s shareholders. If shareholder approval is not obtained, Renovaro will receive a two-year exclusive royalty-free license to Predictive Oncology's biorepository and related technologies as compensation. This merger is expected to bring not only scientific synergies but also potentially enhance the combined company’s position in the capital markets and increase opportunities for business development. Both parties anticipate signing the final agreement no later than February 28, 2025, and the merged company will focus on accelerating drug discovery, reducing development risks, and providing more personalized treatment options for cancer patients. Summary January 2025 has been a transformative month for the biotechnology and pharmaceutical industries. Lantheus Holdings solidified its market position through two key acquisitions, strengthening its competitive edge in the treatment of neuroendocrine tumors, boosting its Alzheimer’s disease diagnostic market presence, and expanding its oncology product line. At the same time, other large pharmaceutical companies have actively participated in the M&A wave. Companies such as Johnson & Johnson, Eli Lilly, and GlaxoSmithKline (GSK) have expanded their product portfolios and technological capabilities through various acquisitions, such as J&J’s acquisition of Intra-Cellular Therapies and Eli Lilly’s investment in Scorpion Therapeutics. These moves significantly enhanced their strength in the fields of precision treatments for mental health and cancer. With advances in technology and changes in market demand, M&A will continue to be a key strategy for companies to acquire new technologies, enter new markets, and address competition. It is expected that AI and digital technologies will play an increasingly important role in drug development, driving innovation and growth in the industry. Meanwhile, the recovery of capital markets may provide support for the growth of more small and mid-sized biotech companies, promoting the diversification of the entire industry. In response to evolving healthcare needs, integration and collaboration within the industry will help accelerate new drug development and improve the quality of medical services, offering more hope to patients worldwide. In summary, the M&A activities in January 2025 highlight several key trends in the biopharmaceutical industry: First, enhancing core competitiveness and technological innovation through mergers and acquisitions; second, addressing unmet medical needs, particularly in neuroscience and oncology; and third, optimizing financial structures and improving business efficiency through restructuring and collaboration. These trends collectively drive industry progress and lay a solid foundation for future growth. How to get the latest progress on drug deals? If you would like to access the latest transaction event information, you can click on the 'Deal' module from the homepage of the Synapse database. Within the Deal module, you can search for global pharmaceutical transaction information using labels such as Drugs, Organization, Target, Drug Type, Deal Date.  Furthermore, you can obtain the original link to the transaction coverage by clicking on the "Deal Name." In the analysis view, you can see the most active assignors, assignees, popular targets, and other dimensions of analysis, as well as the distribution of research and development statuses at the time of the transaction, to help you better understand the search results. The Synapse database also supports the ability to view current transactions from the dimension of "drugs" (by selecting "drugs" from the "Adjust Dimension" dropdown menu above). Targeting transactions involving renowned pharmaceutical companies that are of interest to the industry, such as Merck, Roche, etc., Synapse has identified a group of "leading companies" through drugs that have achieved global sales exceeding 1 billion US dollars in 2022. Transactions involving drugs from these leading companies can be filtered by clicking on the "Leading Company" tag on the left-hand side. In addition to the drug transaction module, you can also view related transaction history on the drug detail page and the institution detail page. Click on the image below to explore new pharmaceutical funding transactions! 

Compared to small molecule drugs, monoclonal antibodies (mAbs) offer several advantages: mAbs provide better specificity, dosing frequency, and limited central nervous system (CNS) penetration. This makes them potentially effective at interacting with challenging in vivo targets that are difficult for small molecule drugs to achieve. mAbs exhibit less interpatient variability in pharmacokinetics and can reduce the risk of immunogenicity through the use of human sequences to remove potential T cell epitopes and by selecting appropriate routes of administration. mAbs not only possess the desired selectivity, good affinity, and longer serum half-life, but also exhibit additional functional effects. These effects are specifically mediated by the Fc region and involve cell killing through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP). Moreover, mAbs can be configured in various formats such as antibody fragments, bispecific and multispecific forms, and antibody-drug conjugates (ADCs). FDA's First GPCR Antibody DrugAimovig™ (erenumab) is an injectable human monoclonal antibody (mAb) co-developed and co-marketed by Novartis and Amgen, indicated for the preventive treatment of migraines in adults. Erenumab acts as a selective calcitonin gene-related peptide (CGRP) receptor antagonist and is administered via subcutaneous injection. Migraine is one of the top ten disabling diseases globally, affecting more than 10% of the population worldwide. Migraines are more complex than simple headaches; they involve debilitating head pain and physical impairment, often accompanied by nausea, vomiting, and tinnitus associated with sound or other sensory disturbances. Migraines also have a significant impact on patients' daily lives, including work productivity and social interactions. Several potential targets for migraine treatment are currently under investigation. These include adenosine receptors (A1/A2A), pituitary adenylate cyclase-activating polypeptide receptors (PACAP), δ-opioid receptors (DOR), and calcitonin gene-related peptide (CGRP) receptors, all of which are G protein-coupled receptors (GPCRs). Other targets include acid-sensing ion channels (ASIC), transient receptor potential channels (TRP), and potassium channels (KATP), which are ion channels. The Development History of Aimovig™ (Erenumab) In 2009, Amgen's team submitted a patent entitled "Human CGRP Receptor Binding Protein," which provided nucleic acids, vectors, and cells encoding antigen-binding proteins. These antigen-binding proteins can inhibit the binding of the CGRP receptor to CGRP, holding potential applications for diseases associated with CGRP receptors, including the treatment and prevention of migraines. In 2012, Amgen officially initiated a Phase 1 clinical trial for AMG 334 (later known as Aimovig™ (erenumab)), assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers and migraine sufferers. This randomized, double-blind, placebo-controlled study included single-dose and ascending multiple-dose arms. Subsequent data from two Phase 1 clinical trials published in 2017 in Clinical Pharmacology and Therapeutics indicated that AMG 334 exhibited non-linear pharmacokinetics from 1 mg to 70 mg, with a linear clearance phase from 70 mg to 210 mg similar to other human immunoglobulin G2 antibodies. A single dose of AMG 334 antibody showed >75% inhibition of capsaicin-induced skin blood flow with no significant dose dependency observed at doses of 21 mg or higher. Overall, AMG 334 was well-tolerated with an acceptable safety profile, supporting further clinical development for migraine prevention. Given the promising Phase 1 clinical trial results, in 2013, Amgen initiated multiple Phase 2 clinical studies, starting with a 12-week Phase 2 clinical trial. From August 6, 2013, to June 30, 2014, 483 patients were randomized to receive placebo (n=160), AMG 334 at 7 mg (n=108), 21 mg (n=108), or 70 mg (n=107). At week 12, the mean change in monthly migraine days was -3.4 days for the 70 mg AMG 334 group compared to -2.3 days for the placebo group. The reductions in monthly migraine days for the 7 mg (-2.2 days) and 21 mg (-2.4 days) AMG 334 groups were not significantly different from the placebo. These results suggested that the 70 mg dose of AMG 334 could be a potential therapy for preventing episodic migraines, warranting further investigation in larger Phase 3 trials. Subsequently, participants from the 12-week double-blind study entered an open-label extension study, receiving 70 mg of AMG 334 every 4 weeks over a longer period. Among the 383 participants, the median treatment duration with AMG 334 was 575 days (range 28-822 days). By week 64, 65%, 42%, and 26% of participants achieved ≥50%, ≥75%, and 100% reduction in monthly migraine days, respectively. The mean HIT-6 score decreased from 60.2 (6.3) at baseline to 51.7 (9.2) at week 64. Improvements in MSQ and MIDAS scores were sustained through week 64. The long-term efficacy and safety of AMG 334 for migraine prevention were demonstrated in the results of this 5-year open-label extension phase of a randomized clinical trial. The world's first GPCR monoclonal antibody drugMogamulizumab (Poteligeo), a humanized, afucosylated IgG1 monoclonal antibody specifically targeting CCR4, was developed by Kyowa Hakko Kirin in Japan. By binding to the N-terminal domain of CCR4, mogamulizumab induces antibody-dependent cellular cytotoxicity. Mogamulizumab was first approved in Japan in 2012 for the treatment of relapsed or refractory CCR4+ adult T-cell leukemia/lymphoma (ATCL) and was later approved in 2014 for relapsed or refractory CCR4+ cutaneous T-cell lymphoma (CTCL). In August and November 2018, the FDA and EMA respectively approved mogamulizumab for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy. According to results from a phase 3 clinical study published in The Lancet Oncology in 2018, mogamulizumab significantly extended progression-free survival compared to the small molecule drug vorinostat, offering a new effective treatment option for patients with cutaneous T-cell lymphoma. The World's First GPCR Bispecific Antibody DrugTalquetamab is a bispecific T-cell engaging antibody that targets both the CD3 receptor on T cells and GPRC5D. GPRC5D, a novel drug target, is a Class C G protein-coupled receptor that is present on some normal cells but overexpressed on myeloma cells. According to information about Talquetamab, this antibody is a fully humanized IgG4 bispecific antibody developed using hybridoma and phage display platforms. It has undergone humanization engineering and is administered subcutaneously. In 2017, the Johnson & Johnson team first submitted a global patent (WO2018017786) for the development of Talquetamab, mentioning that this patent provides an antibody specific to GPRC5D. The provided antibody can be used to diagnose, treat, or monitor the progression, remission, or stabilization of cancers expressing GPRC5D; to determine whether a patient should receive cancer treatment; or to ascertain whether a subject has a cancer expressing GPRC5D and thus may be eligible for GPRC5D-specific anticancer therapy. Surrounding the discovery of GPRC5D x CD3-related antibodies, the Johnson & Johnson team has obtained approval for a total of 8 related patent applications and has conducted multiple clinical studies focusing on multiple myeloma (MM) and relapsed/refractory multiple myeloma (RRMM). In December 2022, the Johnson & Johnson team published an article in the New England Journal of Medicine reporting the results of a Phase 1 clinical trial of the T-cell redirecting GPRC5D bispecific antibody Talquetamab for the treatment of multiple myeloma. The results showed that 232 patients were treated with Talquetamab (102 intravenously, 130 subcutaneously). The median follow-up time was 11.7 months for patients receiving a dose of 405 micrograms and 4.2 months for those receiving 800 micrograms. The response rates were 70% and 64%, respectively. The median duration of response was 10.2 months and 7.8 months, respectively. For the two subcutaneous injection doses (405 micrograms per kilogram weekly and 800 micrograms per kilogram biweekly), common adverse reactions included cytokine release syndrome (in 77% and 80% of patients, respectively), skin-related events (in 67% and 70%), and oral ulcerations (in 63% and 57%); all except one case of cytokine release syndrome were Grade 1 or 2. According to the latest information on the Johnson & Johnson website, the FDA submission includes the most recent clinical research data. The Phase 2 MonumenTAL-1 study of Talquetamab included patients (187 individuals) who had received at least four prior therapies and had not previously received T-cell redirecting therapy. The results demonstrated a significant overall response rate (ORR). In the 0.8 mg/kg SC biweekly regimen, 73.6% of patients achieved ORR. With a median follow-up of nearly 6 months (range: 0 to 9.5 months) from the initial response, 58% of patients achieved a very good partial response (VGPR) or better, with 33% achieving complete response (CR) or better. For the weekly SC dose of 0.4 mg/kg, 73.0% of patients achieved ORR. With a median follow-up of nearly 14 months (range: 0.8 to 15.4) from the initial response, 57% of patients achieved VGPR or better, with 35% achieving CR or better. Representative ADC ProductsAntibody-drug conjugates (ADCs), as an antibody-based therapeutic approach, are among the fastest-growing categories of drugs in cancer treatment. ADCs are essentially monoclonal antibodies (mAbs) that are chemically linked to cytotoxic payloads. These conjugates can specifically recognize and bind to antigens that are expressed at much higher levels on cancer cells compared to normal cells, thereby delivering the drug selectively to the tumor site. Consequently, ADCs improve the therapeutic index by restricting the delivery of potent cytotoxic drugs only to the targeted tumor sites and minimizing nonspecific effects on normal tissues. Currently, 12 ADCs have been approved by the U.S. Food and Drug Administration (FDA), and dozens more are at different stages of preclinical and clinical development. Notably, 8 ADCs have been approved in the past five years alone, underscoring the rapid progress in this field. ADCs have been approved for treating both hematologic malignancies and solid tumors, with indications including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), multiple myeloma (MM), HER2-positive breast cancer, triple-negative breast cancer, gastric cancer, and several other diseases. Since the first ADC was introduced to the market in 2000, ADC technology has undergone extensive improvements to enhance efficacy and safety. As ADC research and development continue, the range of target antigens is also expanding. G-protein-coupled receptors (GPCRs) are emerging as targets for ADCs and have the potential to significantly broaden the current range of ADC target antigens. Multiple GPCRs have already been targeted by ADCs, with two entering Phase I clinical trials. LaNova Medicines: LM-305On May 23, LaNova Medicines signed an exclusive licensing agreement with AstraZeneca for LM-305. Under the terms of the agreement, AstraZeneca will obtain exclusive global rights to research, develop, and commercialize LM-305. LaNova Medicines stands to receive up to $55 million in upfront and near-term payments, and up to $545 million in additional development and commercial milestones, as well as tiered royalties on global net sales. LM-305 is the second antibody-drug conjugate (ADC) developed by LaNova Medicines using its proprietary LX-ADC™ platform. It is the first GPRC5D-targeting macromolecular new drug from China and the first GPRC5D-targeting ADC to enter clinical stages worldwide. GPRC5D is an orphan class C G protein-coupled receptor (GPCR) whose function in human tissues remains unclear. Research indicates that GPRC5D is primarily expressed in malignant bone marrow plasma cells and hair follicles, with minimal or no expression in normal tissues. Because GPRC5D is highly overexpressed in patients with multiple myeloma and its expression is relatively independent of another multiple myeloma target, BCMA, GPRC5D is considered a promising target for treating relapsed/refractory multiple myeloma (RRMM). According to LaNova Medicines' published patents, the discovery of GPRC5D-targeting antibodies involved immunizing mice with GPRC5D protein and screening through hybridomas, resulting in over 20 hybridomas that underwent subsequent antibody characterization. LaNova's team further proceeded with antibody labeling and internalization efficiency detection using pHAb dyes, ADCC activity analysis using reporter gene assays, antibody humanization modifications, and activity evaluations of the humanized antibodies. These studies demonstrated that the optimized humanized antibodies exhibited strong internalization activity in both GPRC5D overexpressing cell lines and endogenous multiple myeloma cell lines. Subsequently, LaNova Medicines developed two ADC products, antibodies 37B9C4 and 58F9G10, each conjugated with the cytotoxic agent MMAE, to study their cytotoxic activity against target cells and antitumor efficacy. Among them, LM-305 exhibited very promising antitumor effects. Takeda: TAK-500 TAK-500 is an ADC (Antibody-Drug Conjugate) product developed by the Takeda team. It specifically targets STING and CCR2 and can selectively activate STING in cells expressing CCR2. This approach facilitates the accumulation of STING agonists within tumors, potentially exerting antitumor activity. The stimulator of interferon genes (STING) is an endoplasmic reticulum membrane protein encoded by the STING1 gene, playing a critical role in innate immunity. When cells are infected by intracellular pathogens, such as viruses, fungi, or intracellular parasites, STING induces the production of type I interferons. Type I interferons protect infected cells and neighboring cells from localized infections through autocrine or paracrine signaling. The chemokine receptor CCR2 is highly expressed in tumor-infiltrating myeloid cells, promoting immune evasion by restricting CD8+ T-cell infiltration. Myeloid cells are present in the tumor microenvironment of most human solid tumors and play a crucial role in influencing local immunoregulatory functions. Activating STING signaling in intratumoral myeloid cells enhances interferon production, thereby boosting local innate and adaptive immunity and synergizing with other antitumor mechanisms. By targeting STING to myeloid cells expressing CCR2, TAK-500 may operate through three potential mechanisms: activating the IFN response, reprogramming inhibitory intratumoral CCR2+ cells to an inflammatory phenotype, and blocking the recruitment of inhibitory tumor-associated macrophages (TAMs). TAK-500 is composed of three parts: an anti-CCR2 IgG1 antibody, a STING agonist TAK-676 developed by Takeda, and a protease-cleavable maleimide linker. TAK-676 is a STING agonist developed by the Takeda team, capable of triggering the STING signaling pathway and activating type I interferons. TAK-676 also acts as an immune system modulator, potentially restoring the immune system and generating durable memory T-cell immunity. TAK-676 is currently undergoing multiple clinical studies for its antitumor effects. According to a China patent (CN 116490244 A) disclosed by Takeda in 2022 regarding STING agonists, the STING agonist TAK-676 (Compound 14) or its pharmaceutically acceptable salts, combined with one or more immune checkpoint inhibitors and radiation, is being developed for cancer therapy. In April 2023, the Takeda team presented a poster at AACR detailing the clinical-stage TAK-500, which can induce STING activation in intratumoral myeloid cells expressing CCR2, producing favorable immunomodulatory effects. Preclinical results indicate that treatment with mTAK-500 in synthetic mouse models with intratumoral myeloid cells expressing CCR2 leads to the accumulation and activation of CD8+ effector T cells in the tumor microenvironment, resulting in significant antitumor activity and improved survival rates. The baseline levels of mMDSCs expressing CCR2 in the mouse models positively correlate with the antitumor response of mTAK-500. An ongoing open-label Phase 1a/1b clinical study (NCT05070247) posted on clinicaltrials.gov is evaluating the safety, tolerability, antitumor activity, pharmacokinetics, and pharmacodynamics of TAK-500 in patients aged ≥18 years with gastroesophageal adenocarcinoma, pancreatic adenocarcinoma, hepatocellular carcinoma, non-squamous non-small cell lung cancer, head and neck squamous cell carcinoma, mesothelioma, or triple-negative breast cancer. Eligibility criteria include disease progression or intolerance to all standard therapies. Daiichi Sankyo: DS-6157aGPR20 is an orphan receptor belonging to the GPCR family class A. Based on research evidence indicating its selective high expression in GIST (Gastrointestinal Stromal Tumor), the Daiichi Sankyo team developed an anti-GPR20 ADC (Antibody-Drug Conjugate) drug, DS-6157a, designed to deliver the cytotoxic DNA topoisomerase I inhibitor exatecan directly to the tumor. In June 2021, the Daiichi Sankyo team published their findings in the journal "Cancer Discovery," reporting that their anti-GPR20 ADC drug DS-6157a exhibited GPR20 expression-dependent antitumor activity in GIST xenograft models, including those resistant to Imatinib, Sunitinib, and Regorafenib. First, the researchers used DNA immunization to generate three rat monoclonal antibodies (mAbs) targeting human GPR20, named 04-046, 04-093, and 04-021. Epitope validation further demonstrated that 04-046 binds to the extracellular ECD1 and ECD2 domains of the receptor. The researchers humanized the 04-046 monoclonal antibody to reduce immunogenicity and used this antibody alongside DXd-ADC technology to create the anti-GPR20 ADC candidate drug DS-6157a. Studies on various GIST tumor models showed that DS-6157a exhibited significant antitumor effects. Additionally, DS-6157a demonstrated superior antitumor efficacy compared to classic tyrosine kinase inhibitors (TKIs), such as the approved drugs Imatinib, Sunitinib, and Regorafenib. Daiichi Sankyo has extensive experience in developing ADC products, having successfully launched the anti-HER2 product Fam-trastuzumab deruxtecan-NXKI, which was approved by the FDA in 2019. This success earned the product various accolades, including priority review, breakthrough therapy designation, fast track designation, and orphan drug status. In 2016, the Daiichi Sankyo team first reported in the "Bioorganic and Medicinal Chemistry Letters" journal the use of DXd-ADC technology to develop the anti-HER2 ADC candidate drug Fam-trastuzumab deruxtecan-NXKI for the treatment of certain types of unresectable or metastatic HER2-positive breast cancer. Based on the preclinical antitumor effects and pharmacokinetic features of DS-6157a, it was deemed a potential new therapy for GIST patients who are refractory, resistant, or intolerant to approved TKIs. Consequently, Daiichi Sankyo registered and initiated a Phase 1 clinical trial for DS-6157a (NCT04276415) in 2020. In June 2023, the Daiichi Sankyo team published the treatment outcomes of DS-6157a in 34 enrolled patients in the journal "Clinical Cancer Research." DS-6157a had good tolerability, with dose-limiting toxicity observed in four patients (11.8%) at doses of 6.4 mg/kg, 9.6 mg/kg, and 12.8 mg/kg. The maximum tolerated dose was determined to be 6.4 mg/kg. Seventeen patients (50.0%) experienced ≥Grade 3 treatment-related adverse events, including decreased platelet count (23.5%), anemia (20.6%), neutrophil count decrease (14.7%), and white blood cell count decrease (11.8%). Four patients (11.8%) experienced serious adverse events related to DS-6157a. Six patients died, with five deaths attributed to disease progression and one death to a DS-6157a-related treatment-emergent adverse event (TEAE). Tumor shrinkage was observed in seven patients (20.6%), and one patient (2.9%) achieved a partial response. Due to the lower-than-expected efficacy, further clinical studies on DS-6157a were discontinued, marking the failure of the first ADC product targeting the orphan receptor GPR20. Novartis: JBH-492JBH-492 is an ADC (antibody-drug conjugate) product developed by the Novartis team, specifically targeting CCR7. It comprises a humanized anti-CCR7 IgG1 antibody linked via a cleavable linker to the antimitotic agent DM4, which inhibits microtubule polymerization and cell division. The development details of this ADC drug are based on the Novartis team's 2018 patent submission titled “Anti-CCR7 Antibody Drug Conjugates.” Researchers established CCR7-stably expressing cell lines, virus-like particles (VLP), and protein constructs. Utilizing the three extracellular loops of CCR7, they constructed a protein construct FabCCR7M1 with a Fab scaffold that can display the extracellular loops of CCR7 in a soluble form, suitable for animal immunization and antibody generation. Through repeated immunizations in Bcl-2 transgenic mice, hybridoma production, FACS screening, antibody purification, and antibody humanization, they produced a series of high-affinity anti-CCR7 antibodies. Multiple humanized anti-CCR7 antibodies exhibited high affinity for CCR7-expressing VLPs, with some showing pH-dependent binding characteristics. Subsequently, researchers used the PathHunter assay to evaluate the agonistic or antagonistic functions of these antibodies. The results indicated that none of the antibodies exhibited agonistic activity. However, several antibodies, including 506E15 and 121G12, were identified as potent antagonists capable of blocking the binding of endogenous ligands. Further investigations involved labeling anti-CCR7 antibodies in the form of CysMab with malemide-pHrodo to study internalization activity. The figure below illustrates the internalization capabilities of three antibodies in various cell lines. Using BLI technology and mutagenesis studies, researchers further identified the epitopes recognized by different antibodies. Ultimately, they selected 121G12 for the generation and characterization of the antibody-drug conjugate, resulting in an ADC with a DAR (drug-to-antibody ratio) of approximately 4. In vivo antitumor studies demonstrated that this series of ADC products exhibited dose-dependent antitumor effects in various tumor xenograft models. Genentech: RG-7636RG-7636 (DEDN6526A) is an ADC product developed by Genentech, consisting of a humanized IgG1 anti-ETB receptor monoclonal antibody MEDN6000A and a potent mitotic inhibitor drug, MMAE. The Genentech team first reported this ETB receptor-specific ADC product for preclinical melanoma studies in the journal Clinical Cancer Research in 2011. Initially, researchers utilized mRNA transcription analysis to identify the characteristic overexpression of the ETB receptor in 28 different metastatic melanoma cell lines. By employing wild-type ETB receptors overexpressed in HEK293 cells or purified ETB receptors as immunogens for BALB/c mice, hybridoma technology was utilized to screen and obtain therapeutic antibodies specifically targeting the extracellular region of the ETB receptor. Antibody 24C7 attracted researchers' attention because ET-1 preincubation treatment could block its binding with the ETB receptor. Further studies indicated that this antibody and ET-1 have mutually exclusive binding with the ETB receptor, competing for the same epitope. Before making efforts to obtain more suitable therapeutic antibodies, researchers attempted to directly assess the role of the ETB receptor in melanoma in vivo growth. By inducing conditional knockdown of ETB receptor expression via shRNA, there was not a significant inhibition of tumor growth observed. These results, similar to the disappointing outcomes of second-phase clinical studies using endothelin receptor antagonists directly for melanoma treatment, prompted researchers to abandon further investigation of receptor inhibition methods. Instead, they sought to develop potential ADC products targeting the ETB receptor. Researchers then focused on another monoclonal antibody called 5E9, as this antibody was capable of carrying labeled fluorescent groups into cells and colocalizing with lysosome marker LAMP1 and early endosome marker EEA1 in staining experiments. One key characteristic of an ADC candidate is the ability to deliver the conjugated drug payload into the cell after binding to the cell surface. The rapid internalization of 5E9 in melanoma cells prompted researchers to adopt an armed antibody approach, conjugating the potent cytotoxic compound MMAE with 5E9. Initially, 5E9 ADC demonstrated specific cytotoxicity relative to control ADC in various cell lines with different levels of ETB receptor expression, which generally correlated with ETB receptor expression. Further research data indicated that knocking out ETB receptor expression resulted in the loss of 5E9 ADC cytotoxicity, whereas overexpressing ETB receptor expression enhanced cytotoxicity. Finally, in in vivo efficacy studies, researchers observed that administering 1, 3, and 6 mg/kg doses of 5E9 ADC or a 6 mg/kg dose of control ADC to animals bearing A2058 and UACC-257 tumors resulted in a sustained decrease in tumor volume with high doses of 5E9 ADC. How to obtain the latest research advancements in the field of biopharmaceuticals?In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

Global Pharmaceutical Research and Development Progress1.AstraZeneca's third-generation EGFR inhibitor, osimertinib (Tagrisso), files for new lung cancer indication in the US On June 10th, AstraZeneca announced that the FDA has accepted and granted priority review to the supplemental New Drug Application (sNDA) for Tagrisso for the treatment of patients with unresectable EGFR-mutated (exon 19 deletion or exon 21 (L858R) mutation) stage III non-small cell lung cancer (NSCLC) following chemoradiation therapy (CRT). The FDA is expected to make a decision on approval in the fourth quarter of this year. The sNDA submission is based on the positive results from the phase III LAURA study. The results demonstrated that patients treated with osimertinib had a significant extension in progression-free survival (PFS) compared to the placebo group (39.1 vs. 5.6 months, HR=0.16, P<0.001); at 12 months, 74% of the osimertinib group were alive and disease-free, compared to 22% in the placebo group; at 36 months, 84% of the osimertinib group and 74% of the placebo group were alive (HR=0.81, P=0.53, data maturity at 20%). In terms of safety, the incidence of grade 3 or higher adverse events was 35% in the osimertinib group versus 12% in the placebo group. Additionally, 48% of the patients in the osimertinib group reported radiation pneumonitis (primarily grades 1-2), compared to 38% in the placebo group. No new safety issues were identified. 2.Eisai/Biogen Initiates BLA Submission for Subcutaneous Injection Therapy for Alzheimer’s Disease On June 11, Eisai and Biogen announced the commencement of the rolling submission to the FDA for a Biologics License Application (BLA) of the subcutaneous injection form of Leqembi for Alzheimer’s disease therapy, intended for weekly administration as a maintenance treatment in patients with mild cognitive impairment or mild dementia stages of the disease. Concurrently, the FDA has accepted the supplemental Biologics License Application (sBLA) for a monthly intravenous injection of Leqembi as a maintenance therapy for the same patient group. The FDA is expected to complete its review of this sBLA by early next year. As part of the maintenance treatment, patients who have completed the bi-weekly initiation phase of Leqembi treatment will receive a monthly intravenous infusion of Leqembi to maintain effective drug concentrations and continue the clearance of highly toxic amyloid fibrils. Data from studies 201, 301, and their open-label extension studies suggest that continuing treatment with Leqembi after an 18-month core treatment phase can prolong its benefits. If the sBLA is approved, the monthly dosing regimen could maintain clinical and biomarker benefits with less burden, making it easier for patients and their caregiving partners to adhere to the treatment over the long term. Moreover, the subcutaneous injection form of Leqembi uses an autoinjector, providing convenience for administration by patients and caregivers. 3.Regeneron's/Sanofi's humanized monoclonal antibody drug Kevzara gains another FDA approval! On June 12, Regeneron Pharmaceuticals announced that the US FDA has approved Kevzara (sarilumab), developed jointly with Sanofi, for the treatment of patients with active polyarticular juvenile idiopathic arthritis (pJIA) who weigh 63 kilograms or more. This condition is a type of arthritis that affects multiple joints. Symptoms of pJia may include joint pain, stiffness, and swelling, which can limit their activities and make it difficult for them to perform certain daily tasks. The FDA's approval for the treatment of the pJIA patient group was based on robust and well-controlled trial results, pharmacokinetic data from adult patients with rheumatoid arthritis, and pharmacokinetic, pharmacodynamic, dose exploration, and safety studies in pediatric pJIA patients. No new adverse reactions or safety issues were found in pJIA patients compared to those with rheumatoid arthritis. The most common drug-related adverse reactions in pJIA patients include nasopharyngitis, neutropenia, upper respiratory infections, and injection site erythema. 4.Kyowa Kirin's New Calcimimetic Agent Evocalcet Receives Approval for Marketing Authorization On June 12th, the latest announcement on the official website of the China National Medical Products Administration (NMPA) confirmed that the new drug marketing application for Evocalcet tablets, a class 5.1 new drug submitted by Kyowa Kirin, has been officially approved. According to publicly available information from Kyowa Kirin, Evocalcet is a novel calcimimetic agent. It has been approved in China for the treatment of secondary hyperparathyroidism (SHPT), a significant manifestation of mineral metabolism disorder and a common, severe complication in patients with chronic kidney disease (CKD). Calcimimetics are allosteric agonists of the calcium-sensing receptor (CaSR) that enhance the sensitivity of CaSR to calcium ions, directly inhibiting the secretion of parathyroid hormone (PTH) and the proliferation of parathyroid cells. According to Kyowa Kirin's public data, Evocalcet was originally discovered by Mitsubishi Tanabe Pharma Corporation. In 2008, Kyowa Kirin obtained the rights to collaborate on research, development, commercialization, and production of Evocalcet in Japan and certain regions of Asia through a licensing agreement. As a second-generation derivative of Cinacalcet (a previously approved calcimimetic agent), Evocalcet not only effectively lowers parathyroid hormone, calcium levels, and fibroblast growth factor 23 (FGF23) but also reduces phosphorous levels by inhibiting bone resorption. Additionally, it shows marked improvements in bioavailability and significantly reduces gastrointestinal side effects and drug-drug interactions. 5.Lilly's New Diabetes Drug, Glucagon Nasal Powder Spray, Approved in China for Severe Hypoglycemia Treatment On June 12, the latest public information on the official website of the National Medical Products Administration (NMPA) of China indicated that the marketing application for the new drug Glucagon Nasal Powder Spray, submitted by Eli Lilly and Company, has been approved. According to an earlier press release from Lilly, this medication, commercially known as Baqsimi, is a glucagon nasal powder spray administered via nasal delivery. The newly approved indication is for the treatment of severe hypoglycemia in diabetes patients aged 4 years and older. Studies show that hypoglycemia lasting for 30 minutes can result in irreversible brain damage. Individuals experiencing severe hypoglycemia typically require glucagon injections, which involve complex procedures such as reconstitution, degassing, and specialized injection techniques. These procedures do not meet the immediate emergency needs for severe hypoglycemia. Baqsimi, a glucagon nasal powder spray, provides a nasal delivery method. According to previously published information from Lilly, it uses a single-dose dispenser that stimulates the liver to release stored glucose into the bloodstream, thereby increasing the patient's blood sugar levels. 6.Novartis Announces Approval of New Indication for JAK Inhibitor Ruxolitinib Phosphate in China On June 13, Novartis announced that its JAK inhibitor, Ruxolitinib Phosphate tablets, had received approval from the China National Medical Products Administration (NMPA) for a new indication: the treatment of chronic graft-versus-host disease (cGVHD) in patients aged 12 and older who have inadequate responses to corticosteroids or other systemic therapies. Previously, in 2023, Ruxolitinib was approved by the NMPA for the treatment of acute GVHD (aGVHD) in patients aged 12 and older who had inadequate responses to corticosteroids or other systemic therapies. Furthermore, it was approved in China in 2017 for adult patients with intermediate- or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) to treat disease-associated splenomegaly or related symptoms. Hematopoietic stem cell transplantation offers a new lease on life for many patients with hematologic diseases; however, 30% to 70% of patients who undergo allogeneic hematopoietic stem cell transplantation face the threat of cGVHD. Corticosteroids remain the frontline treatment for cGVHD, but their effectiveness rate is only 50% to 60%, with some patients progressing to steroid-refractory cGVHD (SR-cGVHD). These patients have poor prognoses, and long-term use of corticosteroids can lead to adverse effects such as infections and osteoporosis, increasing the risk of poor outcomes. There is still a significant unmet medical need for patients with SR-cGVHD. The mechanism of cGVHD is complex, with the primary pathophysiological process being immune-inflammatory reactions, commonly manifesting as fibrosis. The Janus kinase 1 and 2 (JAK1-JAK2) signaling pathway plays a critical role in the steps leading to inflammation and tissue damage. Ruxolitinib, a JAK1/2 inhibitor, can reduce the incidence of cGVHD by inhibiting donor T-cell proliferation, the production of inflammatory cytokines, and the function and activity of Tregs. Additionally, preclinical studies on systemic sclerosis indicate that Ruxolitinib can prevent or ameliorate skin and lung fibrosis, demonstrating anti-fibrotic properties. 7.Bristol Myers Squibb's repotrectinib has received FDA accelerated approval, with Zai Lab holding the rights in China On June 14th, Bristol Myers Squibb announced that the U.S. FDA has granted accelerated approval to its oral tyrosine kinase inhibitor (TKI), Augtyro (repotrectinib), for the treatment of adult and pediatric patients aged 12 and older with locally advanced, metastatic, or surgically unresectable solid tumors that are likely to result in severe morbublic outcomes. These patients must have tumors positive for neurotrophic tyrosine receptor kinase (NTRK) gene fusions, and have either progressed following prior treatment or have no satisfactory alternative therapy options. In China, Zai Lab holds exclusive licensing rights to develop and commercialize repotrectinib in the Greater China region. Repotrectinib has previously been approved in China for treating adult patients with locally advanced or metastatic non-small cell lung cancer that is ROS1-positive. The approval was primarily based on the results from the TRIDENT-1 trial. TRIDENT-1 is a global, multicenter, single-arm, open-label, multi-cohort phase 1/2 clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of Augtyro in patients with locally advanced or metastatic solid tumors positive for NTRK gene fusions (NTRK1/2/3). 8.The clinical data for IN8bio's INB-100, a gamma delta T cell therapy, is impressive, with 100% of patients achieving complete disappearance of tumor cells and maintaining this for one year! On June 14th, IN8bio presented the latest Phase 1 clinical trial results of its proprietary gamma delta T cell therapy, INB-100, at the 2024 European Hematology Association (EHA) Annual Meeting. The results demonstrated that 100% of evaluable leukemia patients (n=10) maintained complete remission (CR) one year after treatment. The data also indicated sustained in vivo expansion of allogeneic gamma delta T cells lasting 365 days post a single treatment. The press release highlighted this as the first instance of persistent expansion and durability demonstrated by an allogeneic cell therapy. INB-100, derived from healthy donors, involves ex vivo expansion and activation of allogeneic gamma delta T cells before infusion into leukemia patients. In this investigator-initiated Phase 1 clinical trial, leukemia patients received a dose of INB-100 following hematopoietic stem cell transplantation. The trial included patients at high risk and those with relapsed acute myeloid leukemia (AML) who had previously undergone multiple treatments, including CAR-T cell therapy. As of May 31, 2024, 100% of the evaluation-ready leukemia patients were alive and continued to maintain complete remission for one year. Historical data published previously indicates that up to 50% of blood cancer patients experience relapse following hematopoietic stem cell transplantation with reduced intensity conditioning, often leading to death shortly after relapse. 9.Innovative antibody therapy Setrusumab yields positive Phase 2 clinical results with zero fracture incidence! Ultragenyx Pharmaceutical and Mereo BioPharma have announced that their investigational therapy, setrusumab, in the Phase 2 segment of the Phase 2/3 ORBIT trial, continues to significantly reduce the fracture incidence in patients with osteogenesis imperfecta (OI) after at least 14 months of follow-up. The median annualized fracture rate reached 0. Concurrently, treatment with setrusumab also significantly and consistently increased lumbar bone mineral density (BMD) by the 12th month. Data revealed that over the two years prior to receiving setrusumab treatment, all 24 patients had a median annualized radiologically confirmed fracture rate of 0.72. After an average of 16 months of treatment, the median annualized fracture rate decreased to 0.00 (p=0.0014; n=24). The annualized fracture rate does not include morphological vertebral fractures and fractures of the fingers, toes, skull, and face, aligning with the primary efficacy endpoint of the Phase 3 study. The reduction in the annualized fracture rate corresponds with the continued increase in BMD. At the 12-month evaluation, setrusumab treatment facilitated an average increase of 22% from baseline in lumbar spine BMD across all age groups (p<0.0001, n=19), which showed further improvement from a 14% increase observed after six months of treatment. For more information on the progress of drug development, please follow the Synapse database.